(AOF) – On the occasion of its quarterly activity update, PCAS said that it remained fully mobilized for an improvement in results in 2022 and a return to positive results in 2023, helped in this by a gradual growth in volumes of Estetrol for Mithras. During the first quarter of the year, the specialist in the development and production of complex molecules for Life Sciences and Innovative Technologies published consolidated sales of 51.2 million euros, down 1.2% over one year and -3% at constant exchange rates.
AOF – LEARN MORE